INmune Bio
INMB
41 hedge funds and large institutions have $37.7M invested in INmune Bio in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 17 increasing their positions, 7 reducing their positions, and 9 closing their positions.
143% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 7
23% more capital invested
Capital invested by funds: $30.6M → $37.7M (+$7.09M)
2% more call options, than puts
Call options by funds: $2.84M | Put options by funds: $2.79M
0% more funds holding
Funds holding: 41 → 41 (0)
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
0.75% less ownership
Funds ownership: 11.65% → 10.9% (-0.75%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ACT Capital Management
Wayne,
Pennsylvania
|
+$5.31M |
| 2 |
Millennium Management
New York
|
+$2.38M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.35M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$1.25M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
-$2.84M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.32M |
| 3 |
EGI
EAM Global Investors
Solana Beach,
California
|
-$2.05M |
| 4 |
ACM
Altium Capital Management
New York
|
-$918K |
| 5 |
BlackRock
New York
|
-$726K |
INMB Hedge Fund Activity: Q3 2021 in Review
41 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q3 2021, worth a combined $37.7M — up 23% from $30.6M a quarter earlier.
Fund positioning in INMB was balanced in Q3 2021: 9 funds opened new positions, 9 closed out, 17 added to existing stakes and 7 trimmed.
The largest buyer was ACT Capital Management, opening a new position worth an estimated $5.31M. The largest seller was EAM Investors, exiting entirely with an estimated $2.84M sold.
- 41 institutional investors held INmune Bio (INMB) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $37.7M of INmune Bio stock for Q3 2021, up 23% quarter-over-quarter.
- 9 funds opened new INmune Bio positions in Q3 2021 and 9 closed out, a net change of 0 holders.
- The largest INmune Bio buyer in Q3 2021 was ACT Capital Management, an estimated $5.31M added.
- The largest INmune Bio seller in Q3 2021 was EAM Investors, an estimated $2.84M sold.
Based on aggregated 13F filings for Q3 2021.